ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...

Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...

ProMIS Neurosciences, a clinical-stage biotechnology company focused on developing therapeutic antibodies for neurodegenerative diseases, has announced a purchase agreement to issue approximately $2.4 ...

Cambridge, Massachusetts, Dec. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...

Guggenheim analyst Eddie Hickman lowered the firm’s price target on ProMIS Neurosciences (PMN) to $5 from $6 and keeps a Buy rating on the shares. ProMIS Neurosciences’ Alzheimer’s candidate, PMN310, ...

ProMIS Neurosciences (NASDAQ:PMN) announced in vitro preclinical data that showed differentiation of PMN310 from other amyloid-beta-directed antibodies at the International Conference on Alzheimer’s ...

PMN is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of PMN shares has decreased $0.61 since the market last closed. This is a 7.38% ...

Patient-reported outcomes are important predictors of morbidity and mortality. The validity and reliability of the Patient Reported Outcomes Measurement Information System (PROMIS) computerized ...

Purpose This study investigated the PROMIS Self-Efficacy Measure for Managing Chronic Conditions (PROMIS-SE) domain distributions and examined the factor structure of the PROMIS-SE. Methods A total of ...

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study The challenge of focusing only on erectile function is ...